Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2005 Oct 18;107(3):1166–1173. doi: 10.1182/blood-2005-06-2325

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2006 by The American Society of Hematology

PMC Copyright notice

Figure 3. — Most cases of nonengrafting AML do not engraft in the B2m^-/- NOD/SCID model. Ten million mononuclear cells from 23 different AML patients were injected into both NOD/SCID () and B2m^-/- NOD/SCID (▪) mice in paired experiments. Six weeks later, bone marrow engraftment was assessed via flow cytometry. AML engraftment was recorded if human CD33⁺/CD45⁺ myeloid cells were present without an accompanying CD19⁺/CD45⁺ B-cell population. Ten of 12 AML cases that failed to engraft in the NOD/SCID assay did not engraft in the B2m^-/- NOD/SCID model.

Inline graphic — Most cases of nonengrafting AML do not engraft in the B2m^-/- NOD/SCID model. Ten million mononuclear cells from 23 different AML patients were injected into both NOD/SCID () and B2m^-/- NOD/SCID (▪) mice in paired experiments. Six weeks later, bone marrow engraftment was assessed via flow cytometry. AML engraftment was recorded if human CD33⁺/CD45⁺ myeloid cells were present without an accompanying CD19⁺/CD45⁺ B-cell population. Ten of 12 AML cases that failed to engraft in the NOD/SCID assay did not engraft in the B2m^-/- NOD/SCID model.